Skip to main content

ZYNYZ

NDC 50881-006 · Incyte Corporation

Generic nameretifanlimab-dlwr
Dosage formINJECTION
RouteINTRAVENOUS
Active ingredient(s)RETIFANLIMAB
Strength25 mg/mL
Pharmacologic classProgrammed Death Receptor-1 Blocking Antibody [EPC], Programmed Death Receptor-1-directed Antibody Interactions [MoA]
Marketing categoryBLA

Packages

50881-006-03 — 1 VIAL, SINGLE-USE in 1 CARTON (50881-006-03) / 20 mL in 1 VIAL, SINGLE-USE

Billed under HCPCS

J9345 — Injection, retifanlimab-dlwr, 1 mg Medicare Part B payment limit (ASP + 6%): $30.98

From the FDA National Drug Code Directory, retrieved August 24, 2026. Product listings are submitted by labelers; FDA does not verify them.